Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462547 · ClinicalTrials.gov registry record · Phase 2
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
A Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, sponsored by Inozyme Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT06462547 is a Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum that is actively recruiting participants, run by Inozyme Pharma. The registered enrollment target is 200 participants, above the 17-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (1076% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT06462547, a Phase 2 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, is actively recruiting participants, sponsored by Inozyme Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
Conditions Studied
Interventions
- DRUG INZ-701
Study Locations (5)
Other
- Necker-Enfants Malades Hospital - Paris
- Universitätsklinikum Hamburg-Eppendorf (UKE) - Hamburg
- VCTC - Oxford
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06462547
The ClinicalTrials.gov registry entry for NCT06462547 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 17-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (1076% higher). The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which INZ-701 is the first listed.
NCT06462547 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, Minnesota, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06462547 about?
NCT06462547 is a clinical study titled "ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency". The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
What is the current status of trial NCT06462547?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-06-19. Estimated completion is 2030-12.
What conditions does trial NCT06462547 study?
This clinical trial studies the following conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Pseudoxanthoma Elasticum, Arterial Calcification, Autosomal Recessive Hypophosphatemic Rickets Type 2, Gene Mutations.
What interventions are being tested in trial NCT06462547?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT06462547?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06462547 being conducted?
This trial has 5 study locations across Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
COMPLETED · Phase 1
Explore more on PlainTrial
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
All registered trials for this condition
Pseudoxanthoma Elasticum
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.